QHSLab uses $335K cash, issues going-concern warning
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
QHSLab, Inc. (USAQ) reported nine-month revenue of $2,253,347, up 13.4% from $1,987,931, with Integrated Service Program revenue rising 63.9% to $1,287,692. Third-quarter revenue fell 8.1% to $677,172 from $737,066 as existing physician customers bought fewer allergy-related products; ISP revenue partly offset the decline. Nine-month gross margin was 67.9%, compared with 66.5%.
Operating expenses contributed to a $99,539 operating loss, versus $95,738 operating income a year earlier; net loss was $119,021 versus $99,156. Operating activities used $334,989 of cash, compared with $80,085 generated in the 2025 nine-month period, and cash stood at $190,464 on September 30, 2026. The company reported a $4,022,572 accumulated deficit and said its losses and negative operating cash flows raise substantial doubt about its ability to continue as a going concern. Management concluded disclosure controls were ineffective, citing inadequate financial-reporting personnel, and identified corrective actions. It also moved to order-based fulfillment and had no inventory on hand at quarter-end.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointNine-month revenue rose 13.4% to $2,253,347.
- Minor pointIntegrated Service Program revenue rose 63.9% to $1,287,692.
Negative
- Major pointQHSLab disclosed substantial doubt about its ability to continue as a going concern.
- Moderate pointThird-quarter revenue declined 8.1% to $677,172.
- Moderate pointNine-month net loss was $119,021, versus $99,156.
- Moderate pointOperating activities used $334,989 of cash, versus $80,085 generated a year earlier.
- Moderate pointDisclosure controls were ineffective as of September 30, 2026.
Filing Explained
The 8,461,550 excluded common-equivalent shares were not issued common stock; conversion or exercise could enlarge the share count.
At
The filing lists 8,461,550 common-equivalent shares excluded from diluted loss per share: 8,044,884 linked to preferred stock and 416,666 warrants.
Series A and Series A-2 preferred stock vote with common stock and rank ahead of it in liquidation; Series A-2 also carries cumulative
The company reported
Key Figures
Key Terms
substantial doubt financial
Integrated Service Program financial
order-based fulfillment model technical
gross margin financial
valuation allowance financial
anti-dilutive financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much revenue did USAQ report for the first nine months of 2026?
What cost reduction does USAQ expect from its vendor changes?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
For
the quarterly period ended
For the period from ______________ to_______________
Commission
file number
(Exact Name Of Registrant As Specified In Its Charter)
(State of Incorporation) |
(I.R.S. Employer Identification No.) |
| (Address of Principal Executive Offices) | (ZIP Code) |
Registrant’s
Telephone Number, Including Area Code:
Securities Registered Pursuant to Section 12(g) of The Act:
| Title of Each Class | Trading Symbol(s) | Name of each Exchange on Which Registered | ||
| NA |
Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.
Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer ☐ | Accelerated filer ☐ |
| Smaller
Reporting Company | |
| Emerging
Growth Company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No
On
November 12, 2026, the Registrant had
TABLE OF CONTENTS
| Item | Description | Page | ||
| PART I - FINANCIAL INFORMATION | ||||
| ITEM 1. | FINANCIAL STATEMENTS. | 4 | ||
| ITEM 2. | MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. | 19 | ||
| ITEM 4. | CONTROLS AND PROCEDURES. | 23 | ||
| PART II - OTHER INFORMATION | ||||
| ITEM 6. | EXHIBITS. | 24 |
| 2 |
Cautionary Note Regarding Forward-Looking Statements
This report contains forward-looking statements. Certain of the matters discussed herein concerning, among other items, our operations, cash flows, financial position and economic performance including, in particular, future sales, product demand, competition and the effect of economic conditions, include forward-looking statements.
Forward-looking statements are predictive in nature and do not relate strictly to historical or current facts and generally include words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates” and similar expressions. Although we believe that the forward-looking statements contained in this report are based upon reasonable assumptions, these statements and other projections contained herein expressing opinions about future outcomes and non-historical information, are subject to uncertainties and, therefore, there is no assurance that the outcomes expressed in these statements will be achieved.
Investors are cautioned that forward-looking statements are not guarantees of future performance and actual results or developments may differ materially from the expectations expressed in forward-looking statements contained herein. Given these uncertainties, you should not place any reliance on these forward-looking statements which speak only as of the date hereof. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. You are advised, however, to consult any additional disclosures we make in our reports filed with the Securities and Exchange Commission (“SEC”).
| 3 |
PART I – FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
| Condensed Consolidated Balance Sheets – September 30, 2026 (unaudited) and December 31, 2025 | 5 |
| Condensed Consolidated Statements of Operations – Three and Nine Months Ended September 30, 2026 and 2025 (unaudited) | 6 |
| Condensed Consolidated Statements of Stockholders’ Equity (Deficit) – Three and Nine Months Ended September 30, 2026 and 2025 (unaudited) | 7 |
| Condensed Consolidated Statements of Cash Flows – Nine Months Ended September 30, 2026 and 2025 (unaudited) | 8 |
| Notes to the Condensed Consolidated Financial Statements (unaudited) | 9 |
| 4 |
QHSLab, Inc.
Condensed Consolidated Balance Sheets
| September 30, 2026 | December 31, 2025 | |||||||
| (Unaudited) | ||||||||
| Assets | ||||||||
| Current Assets: | ||||||||
| Cash and cash equivalents | $ | $ | ||||||
| Accounts receivable, net | ||||||||
| Inventory | - | |||||||
| Prepaid expenses and other current assets | ||||||||
| Total current assets | ||||||||
| Non-current assets: | ||||||||
| Intangible assets, net | ||||||||
| Total assets | $ | $ | ||||||
| Liabilities and Stockholders’ Equity (Deficit) | ||||||||
| Current Liabilities: | ||||||||
| Accounts payable | $ | $ | ||||||
| Other current liabilities | ||||||||
| Due to related party | - | |||||||
| Loans payable | - | |||||||
| Convertible notes payable | - | |||||||
| Total current liabilities | ||||||||
| Non-current Liabilities: | ||||||||
| Loans payable, non-current portion | - | |||||||
| Total non-current liabilities | - | |||||||
| Total liabilities | ||||||||
| Commitments and contingencies (Note 14) | - | - | ||||||
| Stockholders’ Equity (Deficit): | ||||||||
| Preferred stock, | ||||||||
| Preferred stock Series A, $ | ||||||||
| Preferred stock Series A-2, $ | ||||||||
| Preferred stock value | ||||||||
| Common stock, | ||||||||
| Additional paid-in capital | ||||||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Total stockholders’ equity | ||||||||
| Total liabilities and stockholders’ equity | $ | $ | ||||||
See accompanying notes to the unaudited condensed consolidated financial statements.
| 5 |
QHSLab, Inc.
Condensed Consolidated Statements of Operations
| Three Months | Three Months | Nine Months | Nine Months | |||||||||||||
| Ended | Ended | Ended | Ended | |||||||||||||
| September 30, 2026 | September 30, 2025 | September 30, 2026 | September 30, 2025 | |||||||||||||
| (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | |||||||||||||
| Revenue | $ | $ | $ | $ | ||||||||||||
| Cost of revenue | ||||||||||||||||
| Gross profit | ||||||||||||||||
| Operating expenses: | ||||||||||||||||
| General and administrative | ||||||||||||||||
| Sales and marketing | ||||||||||||||||
| Research and development | ||||||||||||||||
| Amortization | ||||||||||||||||
| Total Operating expenses | ||||||||||||||||
| Net operating income (loss) | ( | ) | ( | ) | ||||||||||||
| Other income (expense): | ||||||||||||||||
| Interest expense | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Income (loss) before income taxes | ( | ) | ( | ) | ( | ) | ||||||||||
| Provision on income taxes | - | - | - | - | ||||||||||||
| Net income (loss) | $ | ( | ) | $ | $ | ( | ) | $ | ( | ) | ||||||
| Basic net income (loss) per share | $ | ( | ) | $ | $ | ( | ) | $ | ( | ) | ||||||
| Diluted net income (loss) per share | $ | ( | ) | $ | $ | ( | ) | $ | ( | ) | ||||||
| Weighted average shares outstanding: | ||||||||||||||||
| Basic | ||||||||||||||||
| Diluted | ||||||||||||||||
See accompanying notes to the unaudited condensed consolidated financial statements.
| 6 |
QHSLab, Inc.
Condensed Consolidated Statements of Stockholders’ Equity (Deficit)
(Unaudited)
| Shares | Amount | Shares | Amount | Shares | Amount | Capital | Deficit | (Deficit) | ||||||||||||||||||||||||||||
| Preferred Stock – Series A | Preferred Stock – Series A-2 | Common Stock | Additional Paid-In | Accumulated | Total Stockholders’ Equity | |||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | Capital | Deficit | (Deficit) | ||||||||||||||||||||||||||||
| Balance at January 1, 2026 | $ | $ | $ | $ | $ | ( | ) | $ | ||||||||||||||||||||||||||||
| Net loss | – | – | – | – | – | – | – | ( | ) | ( | ) | |||||||||||||||||||||||||
| Balance at March 31, 2026 | $ | $ | $ | $ | $ | ( | ) | $ | ||||||||||||||||||||||||||||
| Net income | – | – | – | – | – | – | – | |||||||||||||||||||||||||||||
| Balance at June 30, 2026 | $ | $ | $ | $ | $ | ( | ) | $ | ||||||||||||||||||||||||||||
| Net loss | – | – | – | – | – | – | – | ( | ) | ( | ) | |||||||||||||||||||||||||
| Balance at September 30, 2026 | $ | $ | $ | $ | $ | ( | ) | $ | ||||||||||||||||||||||||||||
| Balance at January 1, 2025 | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | ||||||||||||||||||||||||||
| Shares issued for services | – | – | – | – | – | |||||||||||||||||||||||||||||||
| Conversion of notes payable | – | – | – | – | – | |||||||||||||||||||||||||||||||
| Net loss | – | – | – | – | – | – | – | ( | ) | ( | ) | |||||||||||||||||||||||||
| Balance at March 31, 2025 | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | ||||||||||||||||||||||||||
| Net loss | – | – | – | – | – | – | – | ( | ) | ( | ) | |||||||||||||||||||||||||
| Balance at June 30, 2025 | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | ||||||||||||||||||||||||||
| Net income | – | – | – | – | – | – | – | |||||||||||||||||||||||||||||
| Net income (loss) | – | – | – | – | – | – | – | |||||||||||||||||||||||||||||
| Balance at September 30, 2025 | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | ||||||||||||||||||||||||||
See accompanying notes to the unaudited condensed consolidated financial statements.
| 7 |
QHSLab, Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited)
| Nine Months Ended | Nine Months Ended | |||||||
| September 30, 2026 | September 30, 2025 | |||||||
| Operating activities | ||||||||
| Net loss | $ | ( | ) | $ | ( | ) | ||
| Adjustments to reconcile net loss to net cash from operating activities: | ||||||||
| Allowance for credit losses | - | |||||||
| Amortization | ||||||||
| Stock grant compensation | ||||||||
| Shares issued for services | - | |||||||
| Changes in assets and liabilities: | ||||||||
| Accounts receivable | ( | ) | ( | ) | ||||
| Inventory | ||||||||
| Prepaid expenses and other current assets | ( | ) | ( | ) | ||||
| Accounts payable | ( | ) | ( | ) | ||||
| Other current liabilities | ||||||||
| Cash flows from (used by) operating activities | ( | ) | ||||||
| Financing activities: | ||||||||
| Proceeds from related-party borrowings | - | |||||||
| Repayments of related-party borrowings | - | ( | ) | |||||
| Repayments of loan borrowings | ( | ) | ( | ) | ||||
| Cash flows used by financing activities | ( | ) | ( | ) | ||||
| Net change in cash | ( | ) | ||||||
| Cash and cash equivalents – beginning of year | ||||||||
| Cash and cash equivalents - end of period | $ | $ | ||||||
| Supplemental disclosures of cash flow activity: | ||||||||
| Cash paid for interest | $ | $ | ||||||
| Cash paid for taxes | $ | - | $ | - | ||||
| Supplemental noncash investing and financing activity: | ||||||||
| Debt and accrued interest converted to shares of common stock | $ | - | $ | |||||
See accompanying notes to the unaudited condensed consolidated financial statements.
| 8 |
QHSLab, Inc.
Notes to the Unaudited Condensed Consolidated Financial Statements
September 30, 2026
Note 1. The Company
QHSLab, Inc. (the “Company”) was incorporated in Delaware on September 1, 1983. In 2019, the Company became engaged in value-based healthcare, informatics and algorithmic personalized medicine, behavior based remote patient monitoring, chronic care and preventive medicine. On September 23, 2021, the Company changed its state of incorporation from Delaware to Nevada. On April 19, 2022, the Company changed its name to QHSLab, Inc.
The Company is a healthcare technology company focused on improving preventive and value-based care through digital health solutions and point-of-care services. The Company provides healthcare organizations with technology-enabled programs designed to identify patient health risks, support clinical decision-making, improve patient engagement, and create new opportunities for practice revenue.
Note 2. Going Concern
The
accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The
Company had an accumulated deficit of $
Note 3. Basis of Presentation
The condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”). In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of only normal recurring accruals, necessary for a fair statement of financial position, results of operations, and cash flows. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and the accompanying notes included in the Annual Report on Form 10-K for the year ended December 31, 2025.
The accounting policies are described in the “Notes to the Consolidated Financial Statements” in the 2025 Annual Report on Form 10-K and updated, as necessary, in this Form 10-Q. The year-end balance sheet data presented for comparative purposes was derived from audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. The results of operations for the three and nine months ended September 30, 2026 are not necessarily indicative of the operating results for the full year or for any other subsequent interim period.
Segment Information
The Company operates as a single operating segment and single reportable segment. Operating segments are defined as components of a business that can earn revenue and incur expenses and for which discrete financial information is evaluated regularly by the chief operating decision maker (“CODM”) in deciding how to allocate resources and assess performance. The Company’s CODM, the Chief Executive Officer (“CEO”), allocates resources and assesses performance based upon condensed consolidated financial information due to the interconnected relationship of the Company’s products to the same customers, therefore manages its business as a single operating segment. See Note 13 - Segment Information for additional information.
Reclassification of Prior Period Amounts
Certain prior-period amounts have been reclassified to conform to the current-period presentation. Specifically, certain expenses previously classified as Sales and Marketing Expenses have been reclassified to General and Administrative Expenses to better reflect the nature of the underlying costs. These reclassifications had no effect on total operating expenses, loss from operations, net loss, or stockholders’ equity as previously reported.
Accounting Policies
Use of Estimates: The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from the estimates.
| 9 |
Principles of Consolidation: The condensed consolidated financial statements include the accounts of QHSLab, Inc. and its wholly owned subsidiaries USAQ Corporation, Inc., and Medical Practice Income, Inc. All significant inter-company balances and transactions have been eliminated.
Cash and Cash Equivalents: For financial statement presentation purposes, the Company considers those short-term, highly liquid investments with original maturities of three months or less to be cash or cash equivalents. Cash and cash equivalents are maintained at banks believed to be stable, occasionally at amounts in excess of federally insured limits, which represents a concentration of credit risk. The Company has not experienced any losses on deposits of cash and cash equivalents to date.
Accounts
Receivable: The Company extends unsecured credit to its customers on a regular basis. Management monitors the payments on outstanding
balances and estimates future expected credit losses over the life of the receivables based on past experience, current information and
forward-looking economic considerations and adjusts the reserve for uncollectible balances as necessary based on experience. The Company
controls its credit risk related to accounts receivable through credit approvals and monitoring. The Company had two customers that generated
Inventories: Inventories are stated at the lower of cost or estimated net realizable value, on a first-in, first-out, or FIFO, basis. The Company uses actual costs to determine its cost basis for inventories. Inventories consist of only finished goods. Management monitors inventory based on forecasted sales and existing inventory levels. Based on inventory turnover and low on-hand inventory levels, management has determined there was no need for a reserve for slow-moving and obsolete inventories as of December 31, 2025. During the quarter ended September 30, 2026, the Company transitioned to an order-based fulfillment model under which products are purchased and fulfilled based on customer orders rather than maintained as inventory on hand. Accordingly, the Company had no inventory on hand as of September 30, 2026.
Capitalized Software Development Costs: Software development costs for internal-use software are accounted for in accordance with Accounting Standards Codification (“ASC”) 350-40, Internal-Use Software. Development costs that are incurred during the application development stage begin to be capitalized when two criteria are met: (i) the preliminary project stage is completed and (ii) it is probable that the software will be completed and used for its intended function. Capitalization ceases once the software is substantially complete and ready for its intended use.
Costs incurred during the preliminary project stage of software development and post-implementation operating stages are expensed as incurred. Amortization is calculated on a straight-line basis over three years which is the estimated economic life of the software and is included in the cost of revenue on the condensed consolidated statements of operations.
The estimated useful lives of software are reviewed at least annually and the software will be tested for impairment whenever events or changes in circumstances occur that could impact the recoverability of the assets.
Intangible Assets: Intangible assets represent the value the Company paid to acquire assets including a trademark, patent and web domain on June 23, 2021. The allocation of the purchase price to each of these assets was determined based on ASC 805-50-30, Business Combination, Related Issues, Initial Measurement. These assets are accounted for in accordance with ASC 350-30, Intangibles, General Intangibles Other Than Goodwill. The cost of the assets is amortized over the remaining useful life of the assets as follows:
Schedule of Indefinite-Lived Intangible Assets
| U.S. Method Patent | |
| Web Domain | |
| Trademark |
The estimated useful lives and carrying value of the assets are reviewed at least annually or whenever events or circumstances occur which may result in an impact to the value of the assets.
| 10 |
Convertible Notes Payable: The Company accounts for convertible notes deemed conventional and conversion options embedded in non-conventional convertible notes which qualify as equity under Accounting Standards Update (“ASU”) No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including certain convertible instruments and contracts on an entity’s own equity. ASU 2020-06 removes the separation models required for convertible debt with cash conversion features and convertible instruments with beneficial conversion features. It also removes certain settlement conditions that were required for equity contracts to qualify for the derivative scope exception and simplifies the diluted earnings per share calculation for convertible instruments. Accordingly, the Company records, as a discount to convertible notes, the intrinsic value of such conversion options based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt.
Revenue Recognition: Pursuant to ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”) the Company recognizes revenue upon transfer of control of goods, in an amount that reflects the consideration that is expected to be received in exchange for those goods. The Company does not allow for the return of products and therefore does not establish an allowance for returns.
To determine the revenue to be recognized for transactions that the Company determines are within the scope of ASC 606, the Company follows the established five-step framework as follows:
| (i) | identify the contract(s) with a customer; | |
| (ii) | identify the performance obligations in the contract(s); | |
| (iii) | determine the transaction price; | |
| (iv) | allocate the transaction price to the performance obligations in the contract(s); and | |
| (v) | recognize revenue when (or as) the Company satisfies a performance obligation. |
The Company sells allergy diagnostic-related products and immunotherapy treatments to physicians. Revenue is recognized once the Company satisfies its performance obligation which occurs at the point in time when title and possession of products have transitioned to the customer. Beginning April 1, 2025, the Company changed its policy of when title transitions to its customers from upon delivery to upon shipment. Delivery typically occurred within one or two days of shipment, and the Company limited shipping ahead of the end of each reporting period to allow time for delivery. Revenue continues to be recorded when title passes to the customer and, as a result, the change did not have a material impact on the Company’s previously issued consolidated financial statements.
The Company includes shipping and handling fees billed to customers in revenue.
The Company also generates revenue through SaaS agreements whereby the Company provides physicians’ practices access to its proprietary internally-developed software that provides clinical decision support and patient monitoring. The agreements provide for either monthly or annual access to the software. The access to the system begins immediately and revenue is recognized over the agreement term.
The Company provides administrative, billing and clinical decision support services utilizing the Company’s internally-developed software. Revenue is recognized each month based on actual services provided during that month.
The Company has an agreement with a third party to provide clinical research services utilizing its proprietary internally-developed software. The agreement details the performance obligations of the Company and revenue is recognized as those obligations are met.
There are several practical expedients and exemptions allowed under ASC 606 that impact timing of revenue recognition and disclosures. The Company elected to treat similar contracts as a portfolio of contracts, as allowed under ASC 606. The contracts that fall within the portfolio have the same terms and management has the expectation that the result will not be materially different from the consideration of each individual contract.
| 11 |
The Company’s revenues consisted of the following:
Schedule of Revenue Recognition
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Integrated Service Program | $ | $ | $ | $ | ||||||||||||
| Allergy Diagnostic Kit Sales | ||||||||||||||||
| Immunotherapy Treatment Sales | ||||||||||||||||
| Clinical Study Revenue | - | - | ||||||||||||||
| Subscription Revenue | ||||||||||||||||
| Shipping and Handling | ||||||||||||||||
| Training & Other Revenue | ||||||||||||||||
| Total revenue | $ | $ | $ | $ | ||||||||||||
Research
and Development: Research and development expense is primarily related to developing and improving methods related to the Company’s
technology platform. Research and development expenses are expensed when incurred. For the three months ended September 30, 2026 and
2025, there was $
Stock-based Compensation: The Company applies the fair value method of ASC 718, Share Based Payment, in accounting for its stock-based compensation. The standard states that compensation cost is measured at the grant date based on the fair value of the award and is recognized over the service period, which is usually the vesting period. The Company values stock-based compensation at the market price for the Company’s common stock and other pertinent factors at the grant date.
Earnings
Per Common Share: Basic net earnings or (loss) per share is computed using the weighted average number of common shares outstanding
during the period. Diluted net earnings or (loss) per common share is computed using the weighted average number of common and dilutive
equivalent shares outstanding during the period. Dilutive common equivalent shares consist of options and warrants to purchase common
stock (only if those options and warrants are exercisable and at prices below the average share price for the period) and shares issuable
upon the conversion of issued and outstanding preferred stock. Due to the net losses reported for the three and nine months ended September
30, 2026 as well as the nine months ended September 30, 2025, dilutive common equivalent shares were excluded from the computation of
diluted loss per share, as inclusion would be anti-dilutive for the period. For the three months ended September 30, 2025,
Income Taxes: The Company accounts for income taxes in accordance with ASC 740, Income Taxes, which requires recognition of estimated income taxes payable or refundable on income tax returns for the current year and for the estimated future tax effect attributable to temporary differences and carry-forwards. Measurement of deferred income tax is based on enacted tax laws including tax rates, with the measurement of deferred income tax assets being reduced by available tax benefits not expected to be realized.
The
Company has net operating loss carry forwards of $
Recently Issued Accounting Standards
In July 2025, the FASB issued ASU 2025-05, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets (“ASU 2025-05”), which simplifies the estimation of credit losses on current accounts receivable and contract assets arising from transactions accounted for under ASC 606 through the use of a practical expedient. ASU 2025-05 is effective for annual periods beginning after December 15, 2025, and interim reporting periods within that annual period, with early adoption permitted. The Company adopted this standard in 2026 and determined that it did not have a material impact on the Company’s financial statements.
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”), which requires enhanced income tax disclosures, including specific categories and disaggregation of information in the effective tax rate reconciliation, disaggregated information related to income taxes paid, income or loss from continuing operations before income tax expense or benefit, and income tax expense or benefit from continuing operations. ASU 2023-09 is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company adopted ASU 2023-09 beginning with the Form 10-Q for the period ending March 31, 2025 with minimal impact. See Note 12 – Income Taxes.
This Quarterly Report on Form 10-Q does not discuss recent pronouncements that are not anticipated to have a current and/or future impact on or are unrelated to the Company’s financial condition, results of operations, cash flows or disclosures.
| 12 |
Note 4. Accounts Receivable
Accounts receivable is recorded in the condensed consolidated balance sheets when customers are invoiced for revenue to be collected and there is an unconditional right to receive payment. Timing of revenue recognition may differ from the timing of invoicing customers resulting in deferred revenue until the Company satisfies its performance obligation.
Accounts receivable is presented net of an allowance for credit losses that represents future expected credit losses over the life of the receivables based on past experience, current information and forward-looking economic considerations. The beginning and ending balances of accounts receivable, net of allowance, are as follows:
Schedule of Accounts Receivable
| September 30, 2026 | December 31, 2025 | |||||||
| Accounts receivable | $ | $ | ||||||
| Allowance for credit losses | ( | ) | ( | ) | ||||
| Accounts receivable, net | $ | $ | ||||||
Note 5. Capitalized Software and Intangible Assets
Non-current assets consist of the following at September 30, 2026 and December 31, 2025:
Schedule of Intangible Assets
| Estimated Useful Life (in years) | September 30, 2026 | December 31, 2025 | ||||||||||
| Capitalized software | $ | $ | ||||||||||
| Accumulated amortization | ( | ) | ( | ) | ||||||||
| Capitalized software, net | $ | - | $ | - | ||||||||
| Intangible Assets: | ||||||||||||
| U.S. Method Patent | $ | $ | ||||||||||
| Web Domain | N/A | |||||||||||
| Trademark | N/A | |||||||||||
| Total Intangible assets | $ | $ | ||||||||||
| Accumulated amortization | ( | ) | ( | ) | ||||||||
| Intangible assets, net | $ | $ | ||||||||||
Capitalized
software represents the development costs for the Company’s internal-use QHSLab platform software. The Company completed testing
of its QHSLab platform software application at the end of the first quarter of 2022 and began to amortize the capitalized expenses on
a straight-line basis over the useful life of the software. Amortization related to the QHSLab platform was $
The
intangible assets represent the value the Company paid to acquire the trademark “AllergiEnd”, the web domain “AllergiEnd.com”
along with the U.S. Method Patent registration relating to the allergy testing kit and related materials the Company distributes to physician
clients. The Company acquired the intangible assets from MedScience Research Group, Inc. (“MedScience”) as of June 23, 2021
for total consideration of $
The
Company evaluates intangible assets with infinite lives for impairment at least annually and evaluates intangible assets with finite
lives when events or circumstances indicate an impairment may exist.
| 13 |
Note 6. Loans Payable
On
November 12, 2025, the Company entered into a fixed-fee short-term loan with its merchant bank and received $
See additional discussion of loans payable in Note 11 – Related Party Transactions.
Note 7. Convertible Notes Payable
Convertible notes payable at September 30, 2026 and December 31, 2025 consist of the following:
Schedule of Convertible Notes Payable
| September 30, 2026 | December 31, 2025 | |||||||
| Shareholder | $ | - | $ | |||||
| Convertible notes payable gross | - | |||||||
| Less: current portion | - | |||||||
| Non-current portion | $ | - | $ | - | ||||
Effective
May 7, 2021, the Company issued a Convertible Promissory Note in the original principal amount of $
On
December 31, 2025, the Company entered into a Promissory Note Modification and Partial Conversion Agreement (“Modification Agreement”)
with the holder of the Note. As of that date, the outstanding balance of the Note, including accrued interest, was $
Following
the partial conversion, a remaining balance of $
The
balance of the Note was paid off in February 2026. The balance of the Note, including accrued interest, was $
| 14 |
Note 8. Preferred Stock and Private Placement Offering of Common Stock
Issuance of Common Stock and Warrants in a Private Placement Offering
On
December 26, 2025, the Company accepted subscription agreements from two accredited investors for the purchase of $
Series A Preferred Stock
The
outstanding shares of Series A Preferred Stock have a stated value of $
Series A-2 Preferred Stock
The
outstanding shares of Series A-2 Preferred Stock have a stated value of $
Holders of the Series A-2 Convertible Preferred Stock will vote on an as converted basis with the holders of the Company’s common stock and Series A Preferred Stock as to all matters to be voted on by the holders of the common stock. Each Series A-2 Preferred Share shall be entitled to a number of votes equal to five times the number of shares of common stock into which it is then convertible on the applicable record date.
Holders
of the Series A-2 Convertible Preferred Stock are entitled to receive cumulative dividends at an annual rate of
Note 9. Loss Per Common Share
The Company calculates net income or loss per common share in accordance with ASC 260, Earnings Per Share. Basic and diluted net income (loss) per common share were determined by dividing net income (loss) applicable to common stockholders by the weighted average number of common shares outstanding during the period.
The Company’s potentially dilutive shares include shares issuable upon exercise or conversion of outstanding common stock options, common stock warrants, convertible debt and preferred shares, if those options, warrants, debt and preferred shares are exercisable or convertible and at prices below the average share price for the period.
For
the year ended December 31, 2025,
| 15 |
For
the three months ended September 30, 2025,
Schedule of Anti-dilutive Securities Excluded from Calculation of Earnings Per Share
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Common equivalent shares | - | |||||||||||||||
| Stock options | - | - | ||||||||||||||
| Stock warrants | - | - | ||||||||||||||
| Total shares excluded from calculation | ||||||||||||||||
| Antidilutive securities | ||||||||||||||||
Note 10. Stock-based Compensation
During
the nine-month periods ended September 30, 2026 and 2025, there was
There
were
Options outstanding at September 30, 2025 consist of:
Schedule of Options Outstanding and Exercisable
| Date Issued | Number Outstanding | Number Exercisable | Exercise Price | Expiration Date | ||||||||||
| $ | ||||||||||||||
| Total | ||||||||||||||
Warrants outstanding at September 30, 2026 consist of:
Schedule of Warrants Outstanding and Exercisable
| Date Issued | Number Outstanding | Number Exercisable | Exercise Price | Expiration Date | ||||||||||
| $ | ||||||||||||||
| Total | ||||||||||||||
| 16 |
Note 11. Related Party Transactions
Due
to Related Parties: Amounts due to related parties consist of cash advances received from the Company’s principal shareholder.
Some advances bear no interest and are due on demand while a portion has been converted into a loan to the principal shareholder that
provides interest at a rate of
The Company’s CEO and principal shareholder is a shareholder of MedScience. In addition, the CEO provides services to MedScience for which he is compensated.
Note 12. Income Taxes
The Company accounts for income taxes in accordance with ASC 740, Income Taxes, which requires recognition of estimated income taxes payable or refundable on income tax returns for the current year and for the estimated future tax effect attributable to temporary differences and carry-forwards. Measurement of deferred income tax is based on enacted tax laws including tax rates, with the measurement of deferred income tax assets being reduced by available tax benefits not expected to be realized. Given its history of net operating losses, the Company has determined that it is more likely than not that it will not be able to realize the tax benefit of its net operating loss carryforwards. Accordingly, the Company has not recognized a deferred tax asset for this benefit.
The
valuation allowance at September 30, 2026 and December 31, 2025 was $
Reconciliation
between the provision for income taxes and the expected tax benefit using the federal statutory rate of
Schedule of Effective Income Tax Reconciliation
September 30, 2026 | December 31, 2025 | |||||||
| Income tax at federal statutory rate | % | % | ||||||
| Valuation allowance | ( | )% | ( | )% | ||||
| Income tax expense | — | — | ||||||
| 17 |
The
Company has net operating loss carry forwards of $
For the nine-month period ended September 30, 2026, the Company did not record a tax provision. The Company continues to maintain a valuation allowance against its net deferred tax assets, which will be reassessed as additional information becomes available.
Note 13. Segment Information
The
Company operates as
The significant expenses that are regularly provided to the CODM are disclosed in the condensed consolidated statements of operations as a part of the condensed consolidated net income (loss). See the condensed consolidated financial statements for all financial information regarding the Company’s operating segment.
Note 14. Commitments and Contingencies
There are no pending or threatened legal proceedings as of September 30, 2026. The Company has no non-cancellable operating leases.
Note 15. Subsequent Events
Management has evaluated subsequent events through the date of this filing.
| 18 |
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
The following discussion provides information which management believes is relevant to an assessment and understanding of our results of operations and financial condition. The discussion should be read along with our unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2026 and 2025 and notes thereto contained elsewhere in this Report, and our annual report on Form 10-K for the twelve months ended December 31, 2025 including the consolidated financial statements and notes thereto contained in such Report. The following discussion and analysis contains forward-looking statements, which involve risks and uncertainties. Our actual results may differ significantly from the results, expectations and plans discussed in these forward-looking statements. See “Cautionary Note Concerning Forward-Looking Statements.”
Overview
We are a healthcare technology company focused on improving preventive and value-based care through digital health solutions and point-of-care services. The Company provides healthcare organizations with technology-enabled programs designed to identify patient health risks, support clinical decision-making, improve patient engagement, and create new opportunities for practice revenue. As part of our mission, we are providing PCPs and other healthcare providers with the software, training and technology necessary to allow them to treat their patients using value-based healthcare, informatics and personalized medicine. Our digital healthcare, clinical decision support and point of care solutions also support non face to face remote patient and therapeutic monitoring, to address chronic care and preventive medicine and are reimbursable to the medical practice.
Increasingly, regulators and insurance companies recognize what health care technologists have been saying for nearly 20 years, which is that most chronic conditions are better managed with more frequent and short encounters often without a physician’s direct participation, rather than infrequent visits. More health insurers have realized that clinical decision support (“CDS”) technologies such as those provided through our proprietary internally-developed Quality Health System Lab Expert System software (“QHSLab”) can provide the necessary encounters to foster patient compliance in between face to face visits to a physician. As new technologies become available, government health care agencies and health insurers seek to determine the appropriate reimbursement level.
Based on the success of PCPs using our QHSLab allergy diagnostics combined with the products acquired from MedScience Research Group, Inc. (“MedScience”), we are increasing our revenues by charging physicians a monthly subscription fee for the use of QHSLab and soliciting additional PCPs to increase their revenues by using our proven revenue generating QHSLab and AllergiEnd® line of products. We also plan to introduce additional point of care solutions, and digital health programs that PCPs can use in their practices. We strive to design our solution so that in all cases, PCPs will be paid under existing government and private insurance programs, based upon analyses conducted utilizing QHSLab and treatments provided as a result of such analyses.
Our ability to operate profitably is determined by our ability to generate revenues from the licensing of our QHSLab software and the sale of diagnostic related products and treatment protocols and the provision of services through our QHSLab system. Our ability to generate a profit from these sales is determined by our ability to increase the number of physicians using these products which is highly dependent upon the ability of our physician customers to obtain reimbursement for their services. We will continue to upgrade QHSLab in an effort to increase the number of products sold based upon the services it can provide and for which we are able to charge a fee.
Our revenues are, in part, dependent on the ability of our medical practice clients to obtain reimbursement from Medicare, Medicaid, and commercial health insurance providers for clinical services supported by our technology and programs. Government agencies and insurance providers regularly review reimbursement policies, coverage limitation rates, reimbursement rates, documentation requirements and claims adjudication practices to reflect changes in medical practice and the insurance regulations. Changes made by these entities may adversely affect our clients ability to generate revenues and profitability operate their practices, which may reduce demand for our products and services, affect client utilization of our products, result in delayed payments, require adjustments to our service offerings and pricing, and, in extreme circumstances, cause a provider to stop using our products and services entirely. Healthcare reimbursement policies are subject to ongoing review and modification by government and commercial payers, and we cannot predict the timing, nature, or financial impact of future changes. Accordingly, changes in reimbursement policies could materially adversely affect our revenues, operating results, and future growth.
Management continuously monitors developments in healthcare reimbursement in an effort to anticipate changes and adapt our programs and services to evolving payer requirements.
We operate as a single operating segment and single reportable segment. Our CODM, the Chief Executive Officer, allocates resources and assesses performance based upon condensed consolidated financial information and due to the interconnected relationship of our products which are predominately offered to the same class of customer, manages our business as a single operating segment.
| 19 |
Results of Operations during the three and nine months ended September 30, 2026 as compared to the three and nine months ended September 30, 2025
Revenues
For the three months ended September 30, 2026, we generated revenues of $677,172 compared to $737,066 for the three months ended September 30, 2025, representing a decrease of $59,894, or 8.1%. The decrease was primarily attributable to a 37.0% reduction in combined Allergy Diagnostics and Allergen Immunotherapy treatment revenues, partially offset by a 17.4% increase in revenues generated from our Integrated Service Program (“ISP”).
The reduction in allergy-related revenues reflected lower purchasing activity by certain existing physician customers during the quarter. Management is evaluating the extent to which seasonal ordering patterns, physician practice economics, and changes in healthcare insurance affordability and reimbursement policies may have contributed to reduced customer demand. The relative impact of these factors has not yet been established. In September 2026, the Company implemented changes to its vendor relationships expected to reduce the cost of allergy diagnostic kits by approximately 10% to 13%, based on historical product sales mix and revised supplier pricing. These reductions are expected to improve gross margins on future allergy diagnostic kit sales. Despite the decline in allergy-related revenues, the Company continued to experience year-over-year growth in ISP revenues, reflecting the increasing contribution of its technology-enabled healthcare services to its overall revenue mix.
For the nine months ended September 30, 2026, we generated revenues of $2,253,347 compared to $1,987,931 of revenues for the nine months ended September 30, 2025. The increase in revenues in the first nine months of 2026 was attributed to a 63.9% increase in revenues generated from ISP services to $1,287,692 compared to $785,506 during the nine months ended September 30, 2025.
Our revenues consisted of the following:
For the Three Months Ended September 30, | For the Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Integrated Service Program | $ | 421,792 | $ | 359,376 | $ | 1,287,692 | $ | 785,506 | ||||||||
| Allergy Diagnostic Kit Sales | 141,403 | 216,363 | 566,231 | 678,920 | ||||||||||||
| Immunotherapy Treatment Sales | 77,581 | 131,477 | 262,623 | 348,691 | ||||||||||||
| Clinical Study Revenue | - | - | 29,700 | 89,100 | ||||||||||||
| Subscription Revenue | 8,283 | 15,876 | 26,897 | 34,413 | ||||||||||||
| Shipping and Handling | 7,699 | 11,458 | 30,253 | 31,519 | ||||||||||||
| Training & Other Revenue | 20,414 | 2,516 | 49,951 | 19,782 | ||||||||||||
| Total revenue | $ | 677,172 | $ | 737,066 | $ | 2,253,347 | $ | 1,987,931 | ||||||||
Cost of Revenues and Gross Profit
Cost of revenues consists of the cost of AllergiEnd® test kits and allergen immunotherapy pharmacy prepared treatment sets, shipping costs to our customers as well as administrative and revenue sharing services and labor expenses directly related to ISP sales and the amortization of our capitalized software.
For the three months ended September 30, 2026 and 2025, cost of revenues was $208,709 and $243,435, respectively.
The Company generated a gross profit of $468,463 during the three months ended September 30, 2026 compared to $493,631 for the three months ended September 30, 2025. Gross margin increased to 69.2% for the quarter compared to 67.0% during the three months ended September 30, 2025.
For the nine months ended September 30, 2026 and 2025, cost of revenues was $724,297 and $665,341, respectively.
The Company generated gross profit of $1,529,050 during the nine months ended September 30, 2026, compared to $1,322,590 for the nine months ended September 30, 2025. Gross margin increased from 66.5% to 67.9% during the respective periods. The improvement in gross margin was primarily attributable to a favorable shift in revenue mix, including a $502,186 (63.9%) increase in ISP revenue, and operating efficiencies across the Company’s core product lines.
Beginning in September 2026, the Company implemented changes to its vendor relationships that are expected to reduce the cost of allergy diagnostic kits by approximately 10% to 13%. Management anticipates that these cost reductions will contribute favorably to gross margins in future periods as the benefits are realized, although the actual impact will depend on sales volumes and product mix.
As we continue to introduce new products, the gross margins may vary significantly between periods, due, among other things, to differences among our customers and products sold, customer negotiating strengths, and product mix.
Sales and Marketing
Sales and marketing expenses consist primarily of costs associated with selling and marketing our products to PCPs, principally ongoing sales efforts to recruit new PCPs and maintain our relationships with PCPs already using our software and products. These expenses include employee compensation and costs of consultants.
For the three months ended September 30, 2026, sales and marketing expenses totaled $141,060, an increase of $25,892 compared to $115,168 for the three months ended September 30, 2025.
For the nine months ended September 30, 2026, sales and marketing expenses totaled $454,974, an increase of $137,697 compared to $317,277 for the nine months ended September 30, 2025.
The increases in sales and marketing expenses for the three and nine-month periods ended September 30, 2026 compared to the same periods in 2025 relate primarily to increases in marketing expenses and payroll-related expenses as we are investing in more sales and marketing activities to support our increasing ISP revenue. We expect our sales and marketing expenses to continue to increase as we seek to build our customer base and launch additional products. Nevertheless, if we are successful in onboarding a sufficient number of PCPs and maintaining our relationships with these PCPs once they begin to fully utilize our products, sales and marketing expenses could decrease as a percentage of revenues, though we may increase our marketing efforts as funds become available.
General and Administrative
General and administrative expenses consist primarily of personnel and contract labor costs, accounting and legal fees, professional and management consulting services, corporate insurance, and other expenses associated with the administration and operation of the Company.
For the three months ended September 30, 2026, general and administrative expenses totaled $244,705, an increase of $113,290, or 86.2%, compared to $131,415 for the three months ended September 30, 2025.
For the nine months ended September 30, 2026, general and administrative expenses totaled $768,927, an increase of $282,602, or 58.1%, compared to $486,325 for the nine months ended September 30, 2025.
| 20 |
The increase in general and administrative expenses during the periods ended September 30, 2026 was primarily attributable to higher personnel and contract labor costs, additional corporate insurance expenses, and increased administrative and professional service costs. During 2026, the Company introduced Directors and Officers liability insurance as part of its corporate governance and risk management practices, contributing to the increase in insurance expenses compared with the prior-year periods.
Management continues to evaluate its administrative cost structure and implement expense management measures while maintaining the personnel, professional services, and corporate infrastructure necessary to support the Company’s operations and regulatory reporting obligations. Future general and administrative expenses will depend on operating requirements, the level of business activity, and management’s ongoing efforts to improve operating efficiency.
Research and Development
Research and development (“R&D”) expenses primarily consist of costs associated with the development, maintenance, and enhancement of the Company’s proprietary QHSLab technology platform, including software engineering, clinical assessment development, and related digital healthcare programs. R&D costs are expensed as incurred.
For the three months ended September 30, 2026, R&D expenses totaled $115,074, a decrease of $17,695, or 13.3%, compared to $132,769 for the three months ended September 30, 2025.
For the nine months ended September 30, 2026, R&D expenses totaled $350,604, a decrease of $18,562, or 5.0%, compared to $369,166 for the nine months ended September 30, 2025.
Research and development expenses remained relatively consistent with the comparable nine-month period in 2025, reflecting the Company’s continued investment in enhancing its technology platform, expanding its library of clinical assessments, and developing additional digital healthcare programs. Management continues to focus on improving development efficiency while prioritizing technology enhancements and new services that support physician adoption, patient engagement, and revenue growth. Future R&D expenditures will be evaluated in relation to commercial opportunities, operational priorities, and the Company’s objective of achieving sustainable profitability.
Other Income and Expense
For the three months ended September 30, 2026, interest expense decreased by $60,099 to $2,741 from $62,840 for the three months ended September 30, 2025.
| 21 |
For the nine months ended September 30, 2026, interest expense decreased by $175,412 to $19,482 from $194,894 for the nine months ended September 30, 2025.
The decrease is driven by the conversion and settlement of multiple loans during the fourth quarter of 2025 including the elimination of default interest associated with certain of the notes.
Net Operating Income (Loss); Net Income (Loss)
Although revenue increased approximately 13.4% during the nine months ended September 30, 2026, the Company reported an operating loss of $99,539, compared to operating income of $95,738 during the comparable prior-year period. The change in operating results was primarily attributable to increased sales and marketing expenditures and general and administrative expenses associated with expanding the Company’s physician network, commercial operations, and administrative capabilities. These expenditures were partially offset by increased revenue and gross profit, as well as modest reductions in research and development expenses.
For the nine months ended September 30, 2026, the Company reported a net loss of $119,021, compared to a net loss of $99,156 during the comparable prior-year period. The increase in operating expenses was substantially offset by a reduction in interest expense, which decreased from $194,894 in 2025 to $19,482 in 2026, reflecting the Company’s reduced debt obligations.
Management remains focused on improving operating efficiency, expanding recurring revenues, and achieving sustainable profitability. The continued growth of the Company’s Integrated Service Program and investment in its technology platform are expected to support greater operating leverage as revenues increase. Management intends to maintain a disciplined approach to expenditures, prioritizing investments in technology, customer acquisition, and commercialization activities that support revenue growth and improved financial performance. Future operating results will depend on the Company’s ability to increase revenues while effectively managing operating costs.
Liquidity and Capital Resources
Liquidity is a measure of a company’s ability to generate sufficient funds to support its operations, meet financial obligations, and fund future growth.
As of September 30, 2026, the Company had current assets of $519,108, consisting primarily of cash and cash equivalents of $190,464, accounts receivable, net, of $308,923, and prepaid expenses and other current assets of $19,721. Current liabilities totaled $247,114, including accounts payable of $135,616, other current liabilities of $13,682, and amounts due to a related party of $97,816. The Company had no outstanding long-term liabilities as of September 30, 2026.
At December 31, 2025, the Company had current assets of $883,009, including cash and cash equivalents of $636,157, accounts receivable, net, of $190,610, inventory of $35,790, and prepaid expenses and other current assets of $20,452. Current liabilities totaled $449,860, including accounts payable of $326,431, other current liabilities of $17,858, and current portions of loans and convertible notes totaling $105,571. Long-term liabilities consisted of outstanding loan balances of $96,218.
Cash and cash equivalents decreased by $445,693 during the nine months ended September 30, 2026, from $636,157 at December 31, 2025 to $190,464 at September 30, 2026. The decrease primarily reflected $334,989 of cash used in operating activities to support sales growth and $110,704 used in financing activities, principally for the repayment of outstanding debt obligations.
Cash used in operating activities reflected the Company’s operating losses, increased working capital requirements, and continued investment in sales and marketing, technology development, and administrative capabilities to support its expanding physician network and healthcare service programs. Accounts receivable increased by $118,313 during the period, reflecting additional working capital requirements associated with the Company’s revenue growth. These cash requirements were partially offset by reductions in operating liabilities and other changes in working capital.
During the nine-month period, the Company substantially reduced its outstanding debt obligations, including repayment of its remaining loan balances, contributing to a significant reduction in interest expense compared with the prior-year period. Management believes the reduction in debt has strengthened the Company’s financial flexibility and reduced future debt servicing requirements.
Management continues to focus on improving operating cash flow through disciplined expense management, timely collection of accounts receivable, growth in recurring revenues, and improvements in gross margins. The Company is also prioritizing investments in technology, customer acquisition, and commercialization activities that support revenue growth and operating efficiency. Management believes these initiatives may contribute to improved operating leverage as the business expands, although the timing and extent of such improvements remain uncertain.
Notwithstanding these initiatives, the Company incurred a net loss of $119,021 and used $334,989 in cash from operating activities during the nine months ended September 30, 2026. The Company’s ability to meet future operating requirements will depend on its ability to generate sufficient revenues, improve operating cash flows, and collect outstanding receivables. Management’s plans are focused on achieving sustainable profitability and positive operating cash flows; however, the Company has not yet demonstrated sustained profitability from operations, and substantial doubt remains regarding its ability to continue as a going concern.
Additional financing may be required if operating results or cash collections do not meet management’s expectations. Although the reduction in outstanding debt may provide greater financial flexibility, there can be no assurance that additional financing will be available on commercially reasonable terms, if at all. Management will continue to evaluate opportunities to strengthen liquidity and capital resources while maintaining a disciplined approach to operating expenditures and long-term growth initiatives.
| 22 |
Plan of Operation and Funding
The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. As of September 30, 2026, the Company had an accumulated deficit of $4,022,572 and reported a net loss of $119,021 for the nine months then ended. For the year ended December 31, 2025, the Company reported net income of $457,417, principally attributable to a gain of $1,145,695 from the extinguishment of debt. The Company used $334,989 in cash from operating activities during the nine months ended September 30, 2026, compared with cash generated from operating activities of $178,118 for the year ended December 31, 2025.
Despite improvements in revenue, gross margins, and the substantial reduction of outstanding debt obligations, the Company’s history of operating losses and negative operating cash flows raises substantial doubt about its ability to continue as a going concern. The Company’s ability to continue operations is dependent upon achieving sustainable positive operating cash flows or obtaining additional financing, if necessary. The condensed consolidated financial statements do not include any adjustments to the recoverability or classification of assets or the amounts and classification of liabilities that may be necessary should the Company be unable to continue as a going concern.
For the nine months ended September 30, 2026, revenue increased approximately 13.4% compared with the corresponding prior-year period, supported by continued growth in the Company’s ISP. However, increased operating expenses associated with sales and marketing, personnel, and administrative infrastructure exceeded the growth in gross profit, resulting in an operating loss for the period. Management is focused on improving operating efficiency, controlling expenditures, and expanding recurring revenue streams to support sustainable profitability.
As of September 30, 2026, the Company maintained cash and cash equivalents of $190,464, net accounts receivable of $308,923, and positive working capital of $271,994. Management expects working capital requirements to fluctuate with changes in revenue, customer billing and collection cycles, and the timing of operating expenditures. The continued expansion of service-based revenues may result in increased accounts receivable balances, requiring effective collection practices and disciplined working capital management.
The Company has substantially reduced its outstanding debt obligations, resulting in lower interest expense and reduced debt servicing requirements. Management intends to prioritize funding operations through internally generated cash flows and the collection of outstanding receivables while maintaining a disciplined approach to expenditures. The Company’s operating strategy emphasizes growth in higher-margin recurring revenues, improvements in gross margins, and selective investment in technology development, customer acquisition, and commercialization activities that support operational efficiency and long-term growth.
Management continues to evaluate opportunities to improve liquidity and strengthen the Company’s financial position. Although management believes that revenue growth, improved cost management, and anticipated collections of outstanding receivables may support future operating requirements, the Company has not yet demonstrated sustained positive operating cash flows. Accordingly, there can be no assurance that existing resources and future operating cash flows will be sufficient to fund operations over the next twelve months.
If additional capital becomes necessary, the Company may seek financing through debt, equity, or other arrangements. In particular, delays in collecting outstanding accounts receivable or increased working capital requirements may necessitate additional short-term borrowing to support ongoing operations. Management will continue to evaluate available financing alternatives based on the Company’s liquidity requirements, anticipated operating cash flows, financing costs, and the interests of its shareholders. There can be no assurance that additional financing will be available on acceptable terms, if at all.
Additional issuances of equity or convertible securities could result in dilution to existing shareholders and may involve terms or preferences senior to those of the Company’s common stock. Additional borrowings could increase debt servicing obligations, require collateral or restrictive covenants, and limit financial flexibility. There can be no assurance that additional financing will be available on commercially reasonable terms, if at all. If sufficient capital is unavailable when required, the Company may need to reduce operating expenditures, delay planned investments, or limit business expansion, which could adversely affect its operations and financial performance.
The Company’s ability to obtain additional capital, if required, will depend on prevailing financial market conditions, investor demand, and its operating performance. General economic conditions, inflation, healthcare reimbursement policies, geopolitical developments, and other risks described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 may affect both the Company’s operating results and its access to financing.
Management remains focused on strengthening the Company’s financial position through disciplined capital allocation, improved operating cash flows, and the continued development of its technology-enabled healthcare services. The Company’s objective is to achieve sustainable profitability while maintaining the financial flexibility necessary to support future growth opportunities.
ITEM 4. CONTROLS AND PROCEDURES
Evaluation of disclosure controls and procedures.
As of September 30, 2026, our chief executive officer, who is also our chief financial officer conducted an evaluation regarding the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) under the Exchange Act). Based upon the evaluation of these controls and procedures as provided under the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control-Integrated Framework (2013), our chief executive officer/ chief financial officer concluded that our disclosure controls and procedures were ineffective as of the end of the period covered by this report. Many of these deficiencies stem from a lack of adequate personnel, including individuals with experience in financial reporting. Management has identified corrective actions for the weakness and will periodically reevaluate our ability to add personnel and implement improved review procedures as they can be supported by the growth in our business.
Changes in internal controls.
During the quarterly period covered by this report, no changes occurred in our internal control over financial reporting that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
| 23 |
PART II - OTHER INFORMATION
In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, “Item 1. Description of Business, subheading Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, which could materially affect our business, financial condition or future results.
ITEM 6. EXHIBITS.
(a) The following documents are filed as exhibits to this report on Form 10-Q or incorporated by reference herein. Any document incorporated by reference is identified by a parenthetical reference to the SEC filing that included such document.
| Exhibit No. | Description | |
| 3.1 | Articles of Incorporation (incorporated herein by reference to Exhibit B to the Information Statement on Form 14-C filed June 21, 2021) | |
| 3.2 | By-Laws (incorporated herein by reference to Exhibit C to the Information Statement on Form 14-C filed June 21, 2021). | |
| 4.1 | Certificate of Designation authorizing issuance of Series A Preferred Stock (incorporated herein by reference to Exhibit D to the Information Statement on Form 14-C filed June 21, 2021) | |
| 4.2 | Certificate of Designation authorizing the issuance of the Series A-2 Preferred Stock (incorporated herein by reference to Exhibit 3.1 to the Report on Form 8-K filed December 30, 2021) | |
| 31 | Certification of CEO and CFO pursuant to Rule 13a-14(a) or 15d-14(a) of the Exchange Act pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |
| 32 | Certification of CEO and CFO pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| 101.INS | Inline XBRL Instance Document | |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
| 24 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the date indicated.
| QHSLab, Inc. | ||
| By: | /s/ Troy Grogan | |
| Troy Grogan | ||
| Chief Executive Officer and Chief Financial Officer | ||
| Date: | November 12, 2026 | |
| 25 |